2019 Clinic Healthcare Relationship 
Annals of Family Medicine
NOVEMBER 20, 2024
Despite efforts to improve patient-clinician relationships, access to care, and healthcare workflows, annual rates of missed appointments (MA) in the U.S Objective To evaluate the association between patient, health system, geosocial, and environmental factors on the likelihood of MA in Family Medicine clinics.
Annals of Family Medicine
NOVEMBER 20, 2024
Objective: To measure the impact on healthcare system utilization of an intensive primary care (IPC) service from 2019 through 2022. Setting: Safety net hospital/clinic system in Fort Worth, Texas. Conclusions: This IPC program likely improved the health and utilization of a cohort of extremely high utilizers.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Clinical Problem Solvers
OCTOBER 18, 2022
Incarceration negatively affects the physical and mental health of people who are incarcerated as well as their family members and loved ones, and limits access to healthcare before, during, and after incarceration. All healthcare professionals will have patients who are directly or indirectly impacted by the carceral system.
Today's Hospitalist
MAY 9, 2025
Yet this expansion has come with a significant administrative burden, particularly that of clinical documentation. This isn’t about replacing your clinical judgment. Ambient dictation, or ambient clinical documentation, represents a paradigm shift. This isn’t about replacing your clinical judgment. The result?
FDA Law Blog
OCTOBER 14, 2021
Rather, FDA seems intent on regulating RAS devices almost as if they were therapeutics responsible for long term clinical outcomes. It is well out of bounds for FDA to regulate them as if they were a determinant of long term clinical outcomes. We support FDA’s general efforts to inform healthcare providers and protect patient safety.
FDA Law Blog
JANUARY 6, 2022
In general, EKRA prohibits, knowingly and willfully, soliciting, receiving, paying or offering kickbacks in exchange for referring to, inducing a referral to, or using the services of a recovery home, clinical treatment facility, or laboratory. 18 U.S.C. § 18 U.S.C. § 220(e)(2). 18 U.S.C. § 24(b) (emphasis added). 18 U.S.C. § 18 U.S.C. §
FDA Law Blog
JANUARY 6, 2022
In general, EKRA prohibits, knowingly and willfully, soliciting, receiving, paying or offering kickbacks in exchange for referring to, inducing a referral to, or using the services of a recovery home, clinical treatment facility, or laboratory. 18 U.S.C. § 18 U.S.C. § 220(e)(2). 18 U.S.C. § 24(b) (emphasis added). 18 U.S.C. § 18 U.S.C. §
Expert insights. Personalized for you.
130 
Let's personalize your content